Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Condition(s):Atopic DermatitisLast Updated:May 24, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Atopic DermatitisLast Updated:May 24, 2023Completed
Condition(s):Atopic DermatitisLast Updated:July 7, 2022Recruiting
Condition(s):Eczema; Atopic DermatitisLast Updated:January 12, 2016Withdrawn
Condition(s):Atopic DermatitisLast Updated:August 11, 2020Completed
Condition(s):Atopic DermatitisLast Updated:April 9, 2021Completed
Condition(s):Atopic DermatitisLast Updated:June 22, 2022Active, not recruiting
Condition(s):Atopic DermatitisLast Updated:January 22, 2020Completed
Condition(s):Atopic DermatitisLast Updated:August 18, 2020Completed
Condition(s):Atopic Dermatitis; Eczema; DNALast Updated:September 20, 2021Withdrawn
Condition(s):Atopic DermatitisLast Updated:September 14, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.